Evidence map›Paper›PMID 34773280›Full record

ArticleAlcoholism, clinical and experimental research2022

Disentangling the impact of alcohol use and hepatitis C on insulin action in Latino individuals.

Rebecca G Kim, Jonathan Kramer-Feldman, Peter Bacchetti, Barbara Grimes, Esteban Burchard, Celeste Eng, Donglei Hu, Marc Hellerstein, Mandana Khalili

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alcoholism, clinical and experimental research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01858012 (Impact of Hepatitis C on Insulin Sensitivity and Insulin Secretion in Latinos), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01858012 active not recruitingnot on this map

Impact of Hepatitis C on Insulin Sensitivity and Insulin Secretion in Latinos

TypeobservationalSponsorUniversity of California, San FranciscoRan2008 to 2026Enrolled250ConditionsInsulin ResistanceArmsModerate alcohol cessation
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Rebecca G KimDivision of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0001-7965-5760
Jonathan Kramer-FeldmanDivision of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Peter BacchettiDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Barbara GrimesDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Esteban BurchardDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Celeste EngDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Donglei HuDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Marc HellersteinDepartment of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, California, USA.
Mandana KhaliliDivision of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0001-9178-9139
University of California, San Francisco · USUniversity of California, Berkeley · US

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Y. Chen · 1986 to 2026
$30.7M
NRSA Hepatology Training GrantT32DK060414 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mandana Khalili, JACQUELYN J. MAHER · 2002 to 2026
$6.8M
Mentoring Multidisciplinary Patient-Oriented Research in Viral HepatitisK24AA022523 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KHALILI, MANDANA · 2013 to 2023
$1.9M
NIAAA NIH HHS K24 AA022523NIDDK NIH HHS P30 DK026743NIDDK NIH HHS T32 DK060414
6 · The paper itself

Abstract

backgroundAlcohol, insulin resistance (IR), and hepatitis C (HCV) are all significant contributors to adverse outcomes of chronic liver disease. Latinos are disproportionately affected by these risk factors. We investigated the relationship between alcohol use and insulin action in a prospective cohort of Latino individuals with and without HCV.

methodsOne hundred fifty-three nondiabetic Latino individuals (60 HCV+, 93 HCV-) underwent clinical evaluation and metabolic testing; 56 had repeat testing over a median follow-up of 1.5 years. Peripheral IR and hepatic IR were measured via steady-state plasma glucose (SSPG) and endogenous glucose production during a two-step, 240-min insulin suppression test. Insulin secretion (IS) was measured using the graded glucose infusion test. Alcohol use was categorized as none, moderate (≤1 drink/day for women and ≤2 drinks/day for men), and heavy (>moderate). Multivariable models including HCV status assessed associations of alcohol use with baseline SSPG, hepatic IR and IS, and changes in these parameters over time.

resultsOverall, the median age was 44 years, 63.4% were male, 66.7% overweight/ obese, and 31.9% had heavy lifetime alcohol use while 60.4% had moderate lifetime alcohol use. SSPG and IS were similar by levels of alcohol use at baseline and alcohol use was not statistically significantly associated with change in these measures over time. However, lifetime daily heavy alcohol use (vs. not heavy, coef 2.4 μU-mg/kg-min-ml, p = 0.04) and HCV status (coef 4.4 μU-mg/kg-min-ml, p = 0.0003) were independently associated with higher baseline hepatic IR, and current heavy alcohol use was associated with greater change in hepatic IR in follow-up (coef 5.8 μU-mg/kg-min-ml, p = 0.03).

conclusionsIn this cohort of Latino individuals, lifetime and current heavy alcohol use influenced hepatic IR and its change over time. Strategies to decrease rates of heavy alcohol use or increase abstinence along with lifestyle modification and anti-HCV therapy to reduce metabolic risk are critical to prevent adverse liver and metabolic outcomes in Latino individuals.

Indexed as

AdultAlcohol DrinkingCohort StudiesCytochrome P-450 CYP2E1EthanolFemaleGenotypeHepatitis CHispanic or LatinoHumansInsulinInsulin ResistanceInsulin SecretionLiverLiver DiseasesMaleCytochrome P-450 CYP2E1EthanolInsulinalcohol use disorderhepatic insulin resistanceHispanicinsulin secretionsteady-state plasma glucose

Identifiers

PMID34773280
PMCPMC8799492
OpenAlexW3214439645

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.